IDP 107

Drug Profile

IDP 107

Alternative Names: IDP-107

Latest Information Update: 04 Aug 2015

Price : $50

At a glance

  • Originator Dow Pharmaceutical Sciences
  • Class Antiacnes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne vulgaris

Most Recent Events

  • 06 Feb 2012 Dow Pharmaceutical Sciences completes a phase II trial in Acne vulgaris in USA and Canada (NCT01194375)
  • 03 Nov 2011 Dow Pharmaceutical Sciences completes enrolment in a phase II trial in Acne vulgaris in USA and Canada (NCT01194375)
  • 21 Sep 2010 Dow Pharmaceutical Sciences initiates enrolment in a phase II trial in Acne vulgaris in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top